Incannex provides access to advisory firm for Redomicile – Nokturnal

Incannex Healthcare Limite (ASX: IHL) has engaged independent financial planning firm MLS Financial to provide advice to IHL shareholders with self-managed superannuation funds (SMSF), a superannuation fund holding or similar products, on matters associated with the proposed uplisting to U.S. shares on the Nasdaq and delisting of Australian shares on ASX. The purpose of this … Read more

Taylor Wimpey shares edge higher as dividend increased – Nokturnal

Taylor Wimpey was one of the few FTSE 100 gainers on Wednesday morning as the company announced it would increase its dividend despite falling revenues. However, the increased dividend was one of the few bright spots in an otherwise downbeat half-year report. – Advertisement – The well-documented deterioration in the UK housing market was starting … Read more

Albemarle takes $109 million stake in Patriot Battery – Resource World Magazine – Nokturnal

Albemarle Corp. [ALB-NYSE], the U.S. specialty chemicals giant, is making a $109 million strategic investment in Patriot Battery Metals Inc. [PMET-CSE, PMETF-OTCQB, R9GA-FSE]. Under an agreement, Albemarle will subscribe for 7.12 million common shares of Patriot Battery Metals at $15.29 a share, a move that will leave the U.S. company with a 4.9% stake in … Read more

In the blogs: Retention tension – Nokturnal

Little steps with tech; getting rid of clients; cuts and holidays; and other highlights from our favorite tax bloggers. Retention tension EideBailly (https://www.eidebailly.com/taxblog): The Employee Retention Credit is getting congressional attention. And it isn’t praise. Meyers Brothers Kalicka (https://www.mbkcpa.com/insights): The IRS Office of Chief Counsel has issued a memorandum about applying the ERC to businesses … Read more

Reactive Markets add Allocations – nokturnal – Nokturnal

“As our diversity of client base continues to increase we continue to add features that enable any client type or segment to benefit from the lowest latency execution and access to direct liquidity across all FX products and protocols” said Henry Durrant, Head of Business Development at Reactive Markets. “Allocations and sub-account workflows are the … Read more

Loonie Preps for Canadian & US PMI Data – Nokturnal

USD/CAD ANLAYSIS & TALKING POINTS BoC looks to economic data for guidance. Canadian and US manufacturing in focus today. Rising wedge gives hope to CAD bulls. Trade Smarter – Sign up for the nokturnal Newsletter Receive timely and compelling market commentary from the nokturnal team Subscribe to Newsletter CANADIAN DOLLAR FUNDAMENTAL BACKDROP The Canadian dollar … Read more

Fed’s Goolsbee speaking again on Tuesday, 1 August 2023 – Nokturnal

Federal Reserve Bank of Chicago President Austan Goolsbee spoke on Monday: On the agenda for today, at 1400 GMT, 10am US Eastern time the Federal Reserve Bank of Chicago releases pre-recorded welcome remarks of Goolsbee before the Federal Reserve Bank of Chicago Business Smart Week event. Informasi Ekonomi Terkini Berita Forex Terupdate stratégie forex gagnante, … Read more

Unraveling: Top 10 Luxury Watch Brands [2023] – Nokturnal

Certain names stand out in the world of horology as paragons of precision, craftsmanship, and timeless elegance. The luxury watch brands that have left an indelible mark on history and will continue to define elegance for future generations. In this article, we will take a journey through the world of luxury timepieces, looking at the … Read more

PharmAust’s MND trial successfully completes third patient cohort – Nokturnal

PharmAust Limited (ASX: PAA) has completed its third cohort of six participants in its Phase 1/2 clinical trial of its lead drug candidate monepantel (MPL) in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS). The company has now completed the day 28 dosing of the final patient in the third cohort. Importantly, all participants from Cohorts 1, … Read more

Scancell share rise as cancer therapy trials progress – Nokturnal

Scancell shares were 10% higher in earlier trade on Monday after releasing positive news on their ModiFY trial. Scancell said their ModiFY trial had received approval from the safety review committee to expand to study after the most cohort of patients presented no safety concern and one patient displayed regression. – Advertisement – Scancell is … Read more